BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

REMS-Required Training And Certification Under Way

Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.

Man in red shirt preparing for stair run
BMS and bluebird won the race to bring a BCMA-targeting CAR-T to market, but the climb to commercial success begins now • Source: Shutterstock

Bristol Myers Squibb Company and bluebird bio are bringing to market the first chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) and the first CAR-T therapy for multiple myeloma. BMS chief commercialization officer Chris Boerner told Scrip that the initial focus of the Abecma (idecabtagene vicleucel, ide-cel) launch is working to certify the first treatment centers to administer the one-time treatment following US Food and Drug Administration approval on 26 March.

Abecma, which is under review for approval in the EU, was approved by the FDA to treat relapsed or refractory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By 

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By 

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.